Toxicity profile of high‐dose methotrexate in young children with central nervous system tumors
- 22 July 2024
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (10) , e31213
Abstract
High‐dose methotrexate (HD‐MTX) is used in the treatment of children with central nervous system (CNS) tumors; however, toxicity information is limited. We characterized toxicities following 102 administrations of HD‐MTX (4.6–13.5 g/m2) infused over 4 or 24 h in 38 children with a CNS tumor before 6 years of age (2010–2020). Delayed clearance of methotrexate occurred following 24% of infusions. Common Terminology Criteria for Adverse Events v5 grade 2–3 mucositis was observed in 47% of individuals, Grade 4 neutropenia in 76%, and grade 3–4 thrombocytopenia in 58%. No neurotoxicity was observed. HD‐MTX can be safely used with supportive care and monitoring.Keywords
This publication has 9 references indexed in Scilit:
- Population pharmacokinetics of methotrexate and 7-hydroxymethotrexate and delayed excretion in infants and young children with brain tumorsEuropean Journal of Pharmaceutical Sciences, 2023
- CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018Neuro-Oncology, 2022
- High-Dose Chemotherapy in Children with Newly Diagnosed MedulloblastomaCancers, 2022
- MBCL-34. EFFICACY OF METHOTREXATE (MTX) ACCORDING TO MOLECULAR SUB-TYPE IN YOUNG CHILDREN WITH MEDULLOBLASTOMA (MB): A REPORT FROM CHILDREN’S ONCOLOGY GROUP PHASE III TRIAL ACNS0334Neuro-Oncology, 2020
- Efficacy of High-Dose Chemotherapy and Three-Dimensional Conformal Radiation for Atypical Teratoid/Rhabdoid Tumor: A Report From the Children’s Oncology Group Trial ACNS0333Journal of Clinical Oncology, 2020
- Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children’s Oncology Group (ACNS1221)Journal of Clinical Oncology, 2020
- Pharmacokinetic basis for dosing high‐dose methotrexate in infants and young children with malignant brain tumoursBritish Journal of Clinical Pharmacology, 2019
- QuickStats: Brain Cancer Death Rates Among Children and Teens Aged 1–19 Years,* by Sex† and Age Group — United States, 2013–2015MMWR. Morbidity and Mortality Weekly Report, 2017
- Multiagent Chemotherapy and Deferred Radiotherapy in Infants With Malignant Brain Tumors: A Report From the Children’s Cancer GroupJournal of Clinical Oncology, 2005